SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-14 |
| Reported value | $962,154,050 |
| Positions | 73 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ASCENDIS PHARMA A/S | ASND | ORD SHS | $55,006,732 | 206,234 |
| CELCUITY INC | CELC | COM | $52,414,202 | 500,996 |
| COGENT BIOSCIENCES INC | COGT | COM | $49,563,361 | 1,280,707 |
| UROGEN PHARMA LTD | URGN | COM | $47,912,827 | 1,301,979 |
| IMMUNOME INC | IMNM | COM | $42,740,421 | 2,017,009 |
| DIANTHUS THERAPEUTICS INC | DNTH | COM | $38,017,200 | 390,000 |
| RHYTHM PHARMACEUTICALS INC | RYTM | COM | $34,581,515 | 311,461 |
| ORUKA THERAPEUTICS INC | ORKA | COM | $33,576,166 | 352,802 |
| MONTE ROSA THERAPEUTICS INC | GLUE | COM | $26,820,739 | 1,108,295 |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $26,546,565 | 1,214,390 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.